Nascent Sarcopenia Pipeline’s First Target Is Myostatin
This article was originally published in Pharmaceutical Approvals Monthly
Biologics affecting myostatin signaling are at the forefront of the R&D pipeline for sarcopenia, with leading candidates in Phase II from Sanofi/Regeneron, Lilly and Novartis.
You may also be interested in...
Companies developing treatments for sarcopenia ‘have no idea what they're doing’, according to Ray Lipicky, a former director of the FDA’s Cardio-Renal Drug Products Division who spoke as a patient at the US agency’s sarcopenia drug development meeting.
FDA’s patient-focused drug development initiative and its Drug Development Tool for qualifying endpoints are galvanizing efforts to establish sarcopenia as an indication for clinical development in what could be a very significant market of elderly patients with weakness and functional disability.
A full pipeline of symptomatic and disease-modifying treatments for Duchenne will transform a long dormant orphan market into a hotly contested commercial prize. But some issues, foremost the scarcity of trial patients, threaten to stall progress in the field.